KR20090059117A - 7-에틸-10-히드록시캄토테신의 다분지형 고분자 접합체를 사용한 비호치킨성 림프종의 치료방법 - Google Patents

7-에틸-10-히드록시캄토테신의 다분지형 고분자 접합체를 사용한 비호치킨성 림프종의 치료방법 Download PDF

Info

Publication number
KR20090059117A
KR20090059117A KR1020097005140A KR20097005140A KR20090059117A KR 20090059117 A KR20090059117 A KR 20090059117A KR 1020097005140 A KR1020097005140 A KR 1020097005140A KR 20097005140 A KR20097005140 A KR 20097005140A KR 20090059117 A KR20090059117 A KR 20090059117A
Authority
KR
South Korea
Prior art keywords
compound
treatment
lymphoma
hodgkin
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020097005140A
Other languages
English (en)
Korean (ko)
Inventor
푸자 사프라
Original Assignee
엔존 파마슈티컬즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔존 파마슈티컬즈, 인코포레이티드 filed Critical 엔존 파마슈티컬즈, 인코포레이티드
Publication of KR20090059117A publication Critical patent/KR20090059117A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
KR1020097005140A 2006-09-15 2007-08-17 7-에틸-10-히드록시캄토테신의 다분지형 고분자 접합체를 사용한 비호치킨성 림프종의 치료방법 Ceased KR20090059117A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US84493806P 2006-09-15 2006-09-15
US60/844,938 2006-09-15
US86451606P 2006-11-06 2006-11-06
US60/864,516 2006-11-06
US11/704,607 US7462627B2 (en) 2006-02-09 2007-02-09 Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US11/704,607 2007-02-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035602A Division KR20150005721A (ko) 2006-09-15 2007-08-17 7-에틸-10-히드록시캄토테신의 다분지형 고분자 접합체를 사용한 비호치킨성 림프종의 치료방법

Publications (1)

Publication Number Publication Date
KR20090059117A true KR20090059117A (ko) 2009-06-10

Family

ID=39184444

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020097005140A Ceased KR20090059117A (ko) 2006-09-15 2007-08-17 7-에틸-10-히드록시캄토테신의 다분지형 고분자 접합체를 사용한 비호치킨성 림프종의 치료방법
KR1020147035602A Ceased KR20150005721A (ko) 2006-09-15 2007-08-17 7-에틸-10-히드록시캄토테신의 다분지형 고분자 접합체를 사용한 비호치킨성 림프종의 치료방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147035602A Ceased KR20150005721A (ko) 2006-09-15 2007-08-17 7-에틸-10-히드록시캄토테신의 다분지형 고분자 접합체를 사용한 비호치킨성 림프종의 치료방법

Country Status (11)

Country Link
US (3) US7462627B2 (https=)
EP (1) EP2073809A4 (https=)
JP (1) JP2010503691A (https=)
KR (2) KR20090059117A (https=)
CN (1) CN101707888B (https=)
AU (1) AU2007297042B2 (https=)
BR (1) BRPI0716807A2 (https=)
CA (1) CA2662920A1 (https=)
IL (1) IL197122A0 (https=)
MX (1) MX2009002853A (https=)
WO (1) WO2008033643A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
KR20090108082A (ko) * 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
LT2349346T (lt) 2008-09-23 2019-09-25 Nektar Therapeutics Kamptotecino provaistų (pvz., peg-irinotekano) metronominio dozavimo būdas
KR20110075029A (ko) * 2008-10-21 2011-07-05 엔즌 파마슈티칼스, 인코포레이티드 7-에틸-10-하이드록시캄토테신의 다중-암 고분자 컨쥬게이트로 신경모세포종의 치료
CA2760771A1 (en) * 2009-05-04 2010-11-11 Intezyne Technologies, Incorporated Polymer micelles containing sn-38 for the treatment of cancer
US20120171201A1 (en) * 2009-07-22 2012-07-05 Enzon Pharmaceuticals, Inc. Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
PT2501413T (pt) * 2009-11-18 2019-07-10 Nektar Therapeutics Formas de sal de ácido de conjugados de polímero-fármaco
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
MX371201B (es) 2013-10-04 2020-01-22 Prolynx Llc Conjugados de liberación lenta de sn-38.
CN104650342B (zh) * 2013-11-18 2018-07-10 江苏豪森药业集团有限公司 多支链聚合药物前体及其应用
CN108727582B (zh) * 2017-04-21 2021-11-05 博瑞生物医药（苏州）股份有限公司 靶向抗癌偶联物
MX2020007442A (es) 2018-01-12 2020-09-14 Prolynx Llc Protocolo para minimizar la toxicidad de dosificaciones de combinacion y agente formador de imagen para verificacion.
CN110577550A (zh) * 2018-06-08 2019-12-17 遵义医学院 喜树碱-甘氨酸-去甲斑蝥素结合物及其应用
WO2022035843A1 (en) * 2020-08-12 2022-02-17 Nanomedicine Innovation Center, Llc Topoisomerase inhibitors
IL301558A (en) 2020-09-28 2023-05-01 Fundacio Inst De Recerca Biomedica Irb Barcelona Peptidic conjugates of sn38 useful in the treatment of cancer
JPWO2023095741A1 (https=) * 2021-11-25 2023-06-01
WO2023186822A1 (en) 2022-03-28 2023-10-05 Hospital Sant Joan De Deu Peptidic water-soluble delivery system of anticancer drugs

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4473692A (en) * 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US4943579A (en) 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
AU4406793A (en) * 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5736156A (en) 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
TW438775B (en) * 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
JPH10168373A (ja) * 1996-12-12 1998-06-23 Fuji Xerox Co Ltd インクジェット記録用インク及びそれを用いる記録方法
JP3855344B2 (ja) * 1997-02-19 2006-12-06 日本油脂株式会社 ポリオキシアルキレンカルボン酸の製造方法
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) * 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
WO2000021370A1 (en) 1998-10-14 2000-04-20 University Of Kentucky Research Foundation Oligonucleotide delivery systems for camptothecins
US6534293B1 (en) 1999-01-06 2003-03-18 Cornell Research Foundation, Inc. Accelerating identification of single nucleotide polymorphisms and alignment of clones in genomic sequencing
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
EP1176985A2 (en) 1999-04-28 2002-02-06 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
AU4564200A (en) * 1999-04-29 2000-11-17 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
BRPI0014652B1 (pt) 1999-10-12 2016-08-09 Cell Therapeutics Inc fabricação de conjugados de agente terapêutico-poliglutamato
CA2394980C (en) * 1999-12-22 2008-05-13 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
AU2001230864A1 (en) 2000-01-12 2001-07-24 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
WO2001062299A2 (en) * 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
HUP0204562A2 (hu) 2000-03-17 2003-04-28 Cell Therapeutics, Inc. Poliglutaminsav-kamptotecin konjugátumok, eljárás előállításukra és ilyen konjugátumokat tartalmazó gyógyászati készítmények
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6756037B2 (en) * 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
AU2002217981A1 (en) * 2000-11-30 2002-06-11 Cornerstone Pharmaceuticals, Inc. Water-soluble polymer conjugates of triazine derivatives
US20020123401A1 (en) 2001-03-02 2002-09-05 Henry Rassem Ragheb Combination starter-generator
US20020182272A1 (en) * 2001-05-30 2002-12-05 Bruce Halstead Methods of treatment of HIV-associated conditions
JP4123856B2 (ja) * 2001-07-31 2008-07-23 日油株式会社 生体関連物質の修飾剤およびポリオキシアルキレン誘導体の製造方法
WO2003033525A1 (en) 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
EP1441772A2 (en) 2001-10-29 2004-08-04 Nektar Therapeutics Al, Corporation Polymer conjugates of protein kinase c inhibitors
ATE359829T1 (de) 2001-10-30 2007-05-15 Nektar Therapeutics Al Corp Wasserlösliche polymerkonjugate von retinoesäure
US6608076B1 (en) * 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
CA2488347A1 (en) * 2002-06-06 2003-12-18 University Of Washington Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer
ES2377318T3 (es) * 2002-09-06 2012-03-26 Cerulean Pharma Inc. Polímeros a base de ciclodextrina para el suministro de los agentes terapéuticos enlazados covalentemente a ellos
US6649778B1 (en) * 2002-09-20 2003-11-18 Enzon, Inc. Methods of preparing amino acid taxane derivatives and polymer conjugates containing the same
US7879868B2 (en) 2002-10-11 2011-02-01 Novartis Ag Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents
KR101455222B1 (ko) 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
DE60322111D1 (de) 2002-12-31 2008-08-21 Nektar Therapeutics Al Co Verfahren zur herstellung von hydrogelen aus thiosulfonat-zusammensetzungen und ihre verwendungen
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
CA2537336C (en) * 2003-09-17 2013-02-26 Nektar Therapeutics Al, Corporation Multi-arm polymer prodrugs
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
US20050214250A1 (en) * 2003-11-06 2005-09-29 Harris J M Method of preparing carboxylic acid functionalized polymers
KR101276422B1 (ko) * 2004-03-15 2013-06-19 넥타르 테라퓨틱스 Ｈｉｖ 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트
WO2005094332A2 (en) 2004-03-26 2005-10-13 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
KR20080091829A (ko) * 2006-02-09 2008-10-14 엔존 파마슈티컬즈, 인코포레이티드 유방암, 대장암, 췌장암, 난소암 및 폐암 치료용 7―에틸―10―히드록시캄포테신의 다분지형 고분자 접합체
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
KR20090108082A (ko) * 2007-02-09 2009-10-14 엔존 파마슈티컬즈, 인코포레이티드 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법

Also Published As

Publication number Publication date
US20100204261A1 (en) 2010-08-12
CA2662920A1 (en) 2008-03-20
EP2073809A2 (en) 2009-07-01
KR20150005721A (ko) 2015-01-14
EP2073809A4 (en) 2011-04-13
AU2007297042B2 (en) 2013-01-10
WO2008033643A2 (en) 2008-03-20
US8299089B2 (en) 2012-10-30
WO2008033643A3 (en) 2008-12-11
CN101707888B (zh) 2013-05-15
US20070197575A1 (en) 2007-08-23
BRPI0716807A2 (pt) 2013-11-05
US7723351B2 (en) 2010-05-25
MX2009002853A (es) 2009-03-27
JP2010503691A (ja) 2010-02-04
AU2007297042A1 (en) 2008-03-20
CN101707888A (zh) 2010-05-12
IL197122A0 (en) 2009-11-18
US7462627B2 (en) 2008-12-09
US20090074706A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
KR20090059117A (ko) 7-에틸-10-히드록시캄토테신의 다분지형 고분자 접합체를 사용한 비호치킨성 림프종의 치료방법
EP1996208B1 (en) Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
EP2341774B1 (en) Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
US6608076B1 (en) Camptothecin derivatives and polymeric conjugates thereof
JP2010100628A (ja) 高分子量のポリマーを基剤とするプロドラッグ
KR20090108082A (ko) 7-에틸-10-하이드록시캄토테신 다분지형 고분자 접합체를 이용한 내성 또는 불응성 암의 치료방법
US8048891B2 (en) Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
JP2009539879A (ja) インデノイソキノリン放出性ポリマー複合体

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20090312

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120817

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20131031

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140820

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20131031

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20141120

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20140820

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2014101007169

Request date: 20141120

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20141218

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20141120

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20141120

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20120817

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20090506

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20090317

Patent event code: PB09011R02I

J121 Written withdrawal of request for trial
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20141226

PJ1201 Withdrawal of trial

Patent event code: PJ12011R01D

Patent event date: 20141226

Comment text: Written Withdrawal of Request for Trial

Appeal identifier: 2014101007169

Request date: 20141120

Appeal kind category: Appeal against decision to decline refusal

WITB Written withdrawal of application
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20141120

Effective date: 20150119

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20150119

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20141120

Decision date: 20150119

Appeal identifier: 2014101007169